Oncology

News

BMS strikes again, with $4.1bn RayzeBio takeover bid

Bristol-Myers Squibb is having a busy holiday period, signing a $4.1 billion deal to acquire cancer drug developer RayzeBio – its second multibillion-dollar M&A deal i

News

Final obstacles in front of Pfizer, Seagen merger fall

Pfizer is expecting to close its $43 billion acquisition of antibody-drug conjugate (ADC) pioneer Seagen tomorrow, after receiving all the required regulatory approvals fo

News

Digitised pathology resource will speed HIV cancer R&D

A collection of clinical specimens that has been gathered from people living with HIV for almost 30 years has been given a digital makeover with the help of computational

R&D

Biofidelity’s ASPYRE: The future is bright for oncology

Genomic technology company Biofidelity has announced the launch of ASPYRE-Lung reagents (RUO) for research use, marking its second product launch this year, with the aim of providing simple

News

Merck grabs late-stage oncology drug from China’s Abbisko

Germany’s Merck KGaA is paying Chinese biotech Abbisko Therapeutics $70 million upfront for rights to a drug in phase 3 testing for tenosynovial giant cell tumour (TGCT), a rare disea

News

AbbVie agrees $10.1bn deal to buy ImmunoGen

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar

BMS strikes again, with $4.1bn RayzeBio takeover bid

Final obstacles in front of Pfizer, Seagen merger fall

Digitised pathology resource will speed HIV cancer R&D

Biofidelity’s ASPYRE: The future is bright for oncology

Merck grabs late-stage oncology drug from China’s Abbisko

AbbVie agrees $10.1bn deal to buy ImmunoGen

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks